[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyCTsMuYlLSgKe7D2m9aO3OMwpeGBRYCwkRvo2r2qNd0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Wuerzburg University Hospital",[4],95,false,21,7,26727,4,80,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Adrenal Insufficiency",8,{"name":18,"count":11},"Gingivitis",{"name":20,"count":21},"Periodontitis",3,{"name":23,"count":21},"Rare Diseases",{"name":25,"count":21},"Fabry Disease",{"name":27,"count":21},"Multiple Myeloma",{"name":29,"count":21},"Prostate Cancer",{"name":31,"count":32},"Acute Kidney Injury",2,[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03948035","Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","2029-08","Elotuzumab",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,74,92,110,128,154,172,198,223,252,270,288,314,332,356,381,406,430,456,479,506,524,542,568],{"intervention":38,"totalTrials":48,"cells":49},1,{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":57,"PHASE4":70,"NA":72},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":52},[],{"trials":58,"activeCount":48,"soonestReadout":37},[59],{"nctId":35,"briefTitle":36,"status":60,"phases":61,"primaryCompletion":37,"completion":37,"start":62,"enrollment":63,"conditions":64,"interventions":66},"ACTIVE_NOT_RECRUITING",[43],"2018-08-28",576,[65],"Newly Diagnosed Multiple Myeloma",[38,67,68,69],"Carfilzomib","Lenalidomide","Dexamethasone",{"trials":71,"activeCount":52},[],{"trials":73,"activeCount":52},[],{"intervention":67,"totalTrials":48,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":88,"NA":90},{"trials":77,"activeCount":52},[],{"trials":79,"activeCount":52},[],{"trials":81,"activeCount":52},[],{"trials":83,"activeCount":48,"soonestReadout":37},[84],{"nctId":35,"briefTitle":36,"status":60,"phases":85,"primaryCompletion":37,"completion":37,"start":62,"enrollment":63,"conditions":86,"interventions":87},[43],[65],[38,67,68,69],{"trials":89,"activeCount":52},[],{"trials":91,"activeCount":52},[],{"intervention":68,"totalTrials":48,"cells":93},{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":106,"NA":108},{"trials":95,"activeCount":52},[],{"trials":97,"activeCount":52},[],{"trials":99,"activeCount":52},[],{"trials":101,"activeCount":48,"soonestReadout":37},[102],{"nctId":35,"briefTitle":36,"status":60,"phases":103,"primaryCompletion":37,"completion":37,"start":62,"enrollment":63,"conditions":104,"interventions":105},[43],[65],[38,67,68,69],{"trials":107,"activeCount":52},[],{"trials":109,"activeCount":52},[],{"intervention":69,"totalTrials":48,"cells":111},{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":118,"PHASE4":124,"NA":126},{"trials":113,"activeCount":52},[],{"trials":115,"activeCount":52},[],{"trials":117,"activeCount":52},[],{"trials":119,"activeCount":48,"soonestReadout":37},[120],{"nctId":35,"briefTitle":36,"status":60,"phases":121,"primaryCompletion":37,"completion":37,"start":62,"enrollment":63,"conditions":122,"interventions":123},[43],[65],[38,67,68,69],{"trials":125,"activeCount":52},[],{"trials":127,"activeCount":52},[],{"intervention":129,"totalTrials":48,"cells":130},"Volulyte",{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":152},{"trials":132,"activeCount":52},[],{"trials":134,"activeCount":52},[],{"trials":136,"activeCount":52},[],{"trials":138,"activeCount":52},[],{"trials":140,"activeCount":52},[141],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":52,"conditions":148,"interventions":150},"NCT02587078","Volume Therapy With Crystalloids and Colloids and Hemodynamic Monitoring in Patients With Severe Sepsis","WITHDRAWN",[44],"2013-06","2013-03",[149],"Severe Sepsis",[129,151],"Jonosteril",{"trials":153,"activeCount":52},[],{"intervention":151,"totalTrials":48,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":170},{"trials":157,"activeCount":52},[],{"trials":159,"activeCount":52},[],{"trials":161,"activeCount":52},[],{"trials":163,"activeCount":52},[],{"trials":165,"activeCount":52},[166],{"nctId":142,"briefTitle":143,"status":144,"phases":167,"primaryCompletion":146,"completion":146,"start":147,"enrollment":52,"conditions":168,"interventions":169},[44],[149],[129,151],{"trials":171,"activeCount":52},[],{"intervention":173,"totalTrials":48,"cells":174},"Aclasta",{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":194,"NA":196},{"trials":176,"activeCount":52},[],{"trials":178,"activeCount":52},[],{"trials":180,"activeCount":52},[],{"trials":182,"activeCount":52},[183],{"nctId":184,"briefTitle":185,"status":186,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT01348269","Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome","COMPLETED",[43],"2015-08-26","2011-05",48,[192],"Bone Marrow Edema",[173],{"trials":195,"activeCount":52},[],{"trials":197,"activeCount":52},[],{"intervention":199,"totalTrials":48,"cells":200},"Burosumab",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":219,"NA":221},{"trials":202,"activeCount":52},[],{"trials":204,"activeCount":52},[],{"trials":206,"activeCount":52},[],{"trials":208,"activeCount":52},[209],{"nctId":210,"briefTitle":211,"status":186,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT04695860","Anti-FGF23 (Burosumab) in Adult Patients With XLH",[43],"2023-03-17","2021-01-07",36,[217],"X-linked Hypophosphatemia",[199],{"trials":220,"activeCount":52},[],{"trials":222,"activeCount":52},[],{"intervention":224,"totalTrials":48,"cells":225},"Lenalidomide, Bortezomib",{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":248,"NA":250},{"trials":227,"activeCount":52},[],{"trials":229,"activeCount":52},[],{"trials":231,"activeCount":52},[],{"trials":233,"activeCount":52},[234],{"nctId":235,"briefTitle":236,"status":237,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":245},"NCT01685814","Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance","UNKNOWN",[43],"2016-09","2023-12","2012-05",406,[244],"Previously Untreated Symptomatic Multiple Myeloma",[224,246,247],"autologous stem cell transplant","allogeneic stem cell transplant",{"trials":249,"activeCount":52},[],{"trials":251,"activeCount":52},[],{"intervention":246,"totalTrials":48,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":266,"NA":268},{"trials":255,"activeCount":52},[],{"trials":257,"activeCount":52},[],{"trials":259,"activeCount":52},[],{"trials":261,"activeCount":52},[262],{"nctId":235,"briefTitle":236,"status":237,"phases":263,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":264,"interventions":265},[43],[244],[224,246,247],{"trials":267,"activeCount":52},[],{"trials":269,"activeCount":52},[],{"intervention":247,"totalTrials":48,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":284,"NA":286},{"trials":273,"activeCount":52},[],{"trials":275,"activeCount":52},[],{"trials":277,"activeCount":52},[],{"trials":279,"activeCount":52},[280],{"nctId":235,"briefTitle":236,"status":237,"phases":281,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":282,"interventions":283},[43],[244],[224,246,247],{"trials":285,"activeCount":52},[],{"trials":287,"activeCount":52},[],{"intervention":289,"totalTrials":48,"cells":290},"Prednisolone 20 mg\u002F 5 mg",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":310,"NA":312},{"trials":292,"activeCount":52},[],{"trials":294,"activeCount":52},[],{"trials":296,"activeCount":52},[],{"trials":298,"activeCount":52},[299],{"nctId":300,"briefTitle":301,"status":186,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT05638633","Prednisolone and Vitamin B1\u002F6\u002F12 in Patients With Post-Covid-Syndrome",[43],"2025-01-30","2022-11-11",321,[307],"Post-COVID-19 Syndrome",[289,309],"Vitamin B compound",{"trials":311,"activeCount":52},[],{"trials":313,"activeCount":52},[],{"intervention":309,"totalTrials":48,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":328,"NA":330},{"trials":317,"activeCount":52},[],{"trials":319,"activeCount":52},[],{"trials":321,"activeCount":52},[],{"trials":323,"activeCount":52},[324],{"nctId":300,"briefTitle":301,"status":186,"phases":325,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":326,"interventions":327},[43],[307],[289,309],{"trials":329,"activeCount":52},[],{"trials":331,"activeCount":52},[],{"intervention":333,"totalTrials":48,"cells":334},"Methylphenidate, non-retard",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":352,"NA":354},{"trials":336,"activeCount":52},[],{"trials":338,"activeCount":52},[],{"trials":340,"activeCount":52},[],{"trials":342,"activeCount":52},[343],{"nctId":344,"briefTitle":345,"status":186,"phases":346,"primaryCompletion":347,"completion":147,"start":189,"enrollment":348,"conditions":349,"interventions":351},"NCT01351272","Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)",[43],"2012-12",41,[350],"ADHD",[333],{"trials":353,"activeCount":52},[],{"trials":355,"activeCount":52},[],{"intervention":357,"totalTrials":48,"cells":358},"Spironolactone",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":360,"activeCount":52},[],{"trials":362,"activeCount":52},[],{"trials":364,"activeCount":52},[365],{"nctId":366,"briefTitle":367,"status":186,"phases":368,"primaryCompletion":369,"completion":370,"start":347,"enrollment":371,"conditions":372,"interventions":374},"NCT01691053","Mineralocorticoid Receptor Antagonists in End Stage Renal Disease",[42],"2017-02-14","2018-03-28",118,[373],"End Stage Renal Disease \u002F Hemodialysis",[357],{"trials":376,"activeCount":52},[],{"trials":378,"activeCount":52},[],{"trials":380,"activeCount":52},[],{"intervention":382,"totalTrials":48,"cells":383},"100mg prednisone suppository",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":400,"PHASE4":402,"NA":404},{"trials":385,"activeCount":52},[],{"trials":387,"activeCount":52},[],{"trials":389,"activeCount":52},[390],{"nctId":391,"briefTitle":392,"status":186,"phases":393,"primaryCompletion":394,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT02689960","Vaginal Prednisone Administration for Prevention of Adrenal Crisis",[42],"2017-04","2017-06-01","2017-01",12,[15],[382],{"trials":401,"activeCount":52},[],{"trials":403,"activeCount":52},[],{"trials":405,"activeCount":52},[],{"intervention":407,"totalTrials":48,"cells":408},"SLAMF7 CAR-T",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":424,"PHASE4":426,"NA":428},{"trials":410,"activeCount":52},[],{"trials":412,"activeCount":52},[],{"trials":414,"activeCount":52},[415],{"nctId":416,"briefTitle":417,"status":237,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":423},"NCT04499339","A Phase I\u002FIIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma",[41,42],"2025-12","2020-07-22",38,[27],[407],{"trials":425,"activeCount":52},[],{"trials":427,"activeCount":52},[],{"trials":429,"activeCount":52},[],{"intervention":431,"totalTrials":48,"cells":432},"TCM allogeneic humane central memory T cells, cryopreserved",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":434,"activeCount":52},[],{"trials":436,"activeCount":52},[],{"trials":438,"activeCount":52},[439],{"nctId":440,"briefTitle":441,"status":186,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":449},"NCT02758223","Prophylactic Application of Donor-derived TCM After Allogeneic HSCT",[41,42],"2021-05","2016-04",16,[447,448],"Leukemia, Myeloid, Acute","Myelodysplastic Syndromes",[431],{"trials":451,"activeCount":52},[],{"trials":453,"activeCount":52},[],{"trials":455,"activeCount":52},[],{"intervention":457,"totalTrials":48,"cells":458},"RAD",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":460,"activeCount":52},[],{"trials":462,"activeCount":52},[],{"trials":464,"activeCount":52},[465],{"nctId":466,"briefTitle":467,"status":186,"phases":468,"start":469,"enrollment":470,"conditions":471,"interventions":472},"NCT00925821","Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma",[42],"2009-06",146,[27],[457],{"trials":474,"activeCount":52},[],{"trials":476,"activeCount":52},[],{"trials":478,"activeCount":52},[],{"intervention":480,"totalTrials":48,"cells":481},"depletion of regulatory T cells",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":500,"PHASE4":502,"NA":504},{"trials":483,"activeCount":52},[],{"trials":485,"activeCount":52},[],{"trials":487,"activeCount":52},[488],{"nctId":489,"briefTitle":490,"status":186,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT03879512","Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG",[41,42],"2024-07-31","2018-02-07",24,[496],"Childhood Glioblastoma",[480,498,499],"cancer vaccine","checkpoint blockade",{"trials":501,"activeCount":52},[],{"trials":503,"activeCount":52},[],{"trials":505,"activeCount":52},[],{"intervention":498,"totalTrials":48,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":509,"activeCount":52},[],{"trials":511,"activeCount":52},[],{"trials":513,"activeCount":52},[514],{"nctId":489,"briefTitle":490,"status":186,"phases":515,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":516,"interventions":517},[41,42],[496],[480,498,499],{"trials":519,"activeCount":52},[],{"trials":521,"activeCount":52},[],{"trials":523,"activeCount":52},[],{"intervention":499,"totalTrials":48,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":527,"activeCount":52},[],{"trials":529,"activeCount":52},[],{"trials":531,"activeCount":52},[532],{"nctId":489,"briefTitle":490,"status":186,"phases":533,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":534,"interventions":535},[41,42],[496],[480,498,499],{"trials":537,"activeCount":52},[],{"trials":539,"activeCount":52},[],{"trials":541,"activeCount":52},[],{"intervention":543,"totalTrials":48,"cells":544},"Cabozantinib-s-malate",{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":546,"activeCount":52},[],{"trials":548,"activeCount":52},[],{"trials":550,"activeCount":52},[551],{"nctId":552,"briefTitle":553,"status":237,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":561},"NCT03612232","Cabozantinib in Advanced Adrenocortical Carcinoma",[42],"2024-12-31","2025-04-30","2019-06-04",37,[560],"Adrenocortical Carcinoma",[543],{"trials":563,"activeCount":52},[],{"trials":565,"activeCount":52},[],{"trials":567,"activeCount":52},[],{"intervention":569,"totalTrials":48,"cells":570},"recombinant adjuvanted zoster vaccine",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":572,"activeCount":52},[],{"trials":574,"activeCount":52},[],{"trials":576,"activeCount":52},[],{"trials":578,"activeCount":52},[],{"trials":580,"activeCount":52},[],{"trials":582,"activeCount":52},[583],{"nctId":584,"briefTitle":585,"status":237,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":594},"NCT05705180","The Influence of Trained Immunity in COVID-19 Vaccinated Individuals",[],"2023-12-01","2024-12-01","2022-12-01",600,[592,593],"Zoster Varicella","Vaccination; Infection",[569]]